Saluda Medical Pty Ltd

15 articles about Saluda Medical Pty Ltd

• Cigna and EviCore Add Positive Coverage for the Evoke® System

  4/10/2024

  Saluda Medical, Inc. announced that key US commercial payers, including Cigna and EviCore, have updated their policies to include coverage for the use of the Evoke® closed-loop spinal cord stimulation System.

• Saluda Medical Appoints Jim Erickson as Chief Financial Officer

  12/14/2023

  Saluda Medical, Inc. announced the appointment of Jim Erickson as Chief Financial Officer.

• Saluda Medical Receives FDA Approval for Evoke® System MRI Labeling

  9/26/2023

  Saluda Medical, Inc. ("Saluda Medical") today announced that the U.S. Food and Drug Administration (FDA) has approved MRI conditional labeling for the Evoke® System, the first and only precision, dose-control spinal cord stimulation (SCS) therapy powered by SmartLoop™ technology.

• Saluda Medical Announces Publication of Favorable Economic Analysis Demonstrating Cost-Dominance of Evoke® Closed-Loop SCS over Open-Loop SCS

  8/4/2023

  Saluda Medical, Inc. announced the publication of new health economic data in The Clinical Journal of Pain that provides the strongest ever economic case for the use of Evoke® Closed-Loop SCS with physiologic SmartLoop™ technology over open-loop SCS therapy.

• Saluda Medical Announces $150M Equity Financing Led by Wellington Management with Fidelity Management & Research Company and TPG

  4/13/2023

  Saluda Medical Inc. announced the closing of a US $150 million equity financing round led by new investor Wellington Management, with strong support from current investor Fidelity Management & Research Company and new investor TPG.

• EVOKE Presentation Awarded Overall Winner at ASIPP Annual Meeting

  3/22/2023

  Saluda Medical Pty Limited announced that the EVOKE 36-month Study received the Outstanding Achievement in Research Award at the 25th annual meeting of the American Society of Interventional Pain Physicians in National Harbor, MD.

• Saluda Medical Appoints Laureen DeBuono to Board of Directors

  10/4/2022

  Saluda Medical Pty Limited, a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced neural activation and sensing technologies, announced the appointment of Laureen DeBuono to its board of directors.

• 

  BioSpace Movers & Shakers, June 12

  6/12/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Saluda Medical Results of U.S. Evoke Pivotal Study through 12 Months Published in The Lancet Neurology

  12/20/2019

  Demonstrates Evoke® ECAP-Controlled Closed-Loop SCS Provides Statistically Superior Pain Relief Compared to Open-Loop SCS

• Saluda Medical Announces European Commercial Launch of Evoke®, the First and Only ECAP-Controlled, Closed-Loop SCS System for Chronic Pain Relief

  9/16/2019

  World's First Commercial Implants of the Evoke System Completed in The Netherlands

• Saluda Medical Raises $75 Million Equity Financing from Boston Scientific and Redmile Group

  6/28/2019

  Saluda Medical Pty Limited announced that it has secured $75 million in equity financing from Boston Scientific Corporation and Redmile Group LLC to fund the final stages of development through commercialization of its Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation System for the treatment of chronic intractable pain of the trunk and limbs.

• Saluda Medical Secures Debt Financing From Medtronic

  6/27/2019

  Saluda Medical Pty Limited announced that it has secured a four-year term loan agreement with Medtronic, to fund continued development of its Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System for the treatment of chronic intractable pain of the trunk and limbs.

• Saluda Medical Announces Clinical Study Results for Evoke® ECAP-Controlled, Closed-Loop SCS System for the Treatment of Chronic Pain

  6/3/2019

  New Results Highlight the Importance of Objective Neurophysiological Measures and Clinically Meaningful Functional Outcomes

• Saluda Medical Announces New 3-Month, 12-Month and 18-Month Data Featuring Evoke® ECAP-Controlled, Closed-Loop SCS System to be Presented at 14th INS World Congress

  5/20/2019

  11 Presentations - Including 4 Plenary Presentations - to Feature the Evoke System

• Saluda Medical’s Spinal Cord Stimulation System Latest Investment For Biomedical Translation Fund

  9/11/2017